GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Price-to-Owner-Earnings

Pharma Mar (XMAD:PHM) Price-to-Owner-Earnings : (As of May. 22, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Price-to-Owner-Earnings?

As of today (2024-05-22), Pharma Mar's share price is €36.02. Pharma Mar does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pharma Mar's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Pharma Mar was 289.23. The lowest was 4.66. And the median was 33.93.


XMAD:PHM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-22), Pharma Mar's share price is €36.02. Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.11. Therefore, Pharma Mar's PE Ratio for today is 333.52.

As of today (2024-05-22), Pharma Mar's share price is €36.02. Pharma Mar's EPS without NRI for the trailing twelve months (TTM) ended in was €0.09. Therefore, Pharma Mar's PE Ratio without NRI for today is 418.84.

During the past 13 years, Pharma Mar's highest PE Ratio without NRI was 1349.68. The lowest was 8.94. And the median was 25.88.


Pharma Mar Price-to-Owner-Earnings Historical Data

The historical data trend for Pharma Mar's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Price-to-Owner-Earnings Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 4.78 30.82 51.98 -

Pharma Mar Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Mar's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pharma Mar's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Price-to-Owner-Earnings falls into.



Pharma Mar Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharma Mar's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=36.02/-1.77
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Mar  (XMAD:PHM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharma Mar Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar (XMAD:PHM) Business Description

Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar (XMAD:PHM) Headlines